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Summary 
Lung cancer is the cancer disease that takes the most lives. Non-small cell lung 
cancer (NSCLC) is the most common type, and more than half have an incurable 
disease at the time of diagnosis. Chemotherapy can halt the disease but is only 
moderately effective, has some side effects and requires regular hospital visits for 
intravenous infusions. The aim of the current work was to find a more tolerable 
treatment that is easier to administer and to explore how patients balance the benefits 
and disadvantages of treatment.  
We conducted a national study comparing a chemotherapy combination with fewer 
side effects (vinorelbine and gemcitabine; VG) with the most commonly used 
combination in Norway (vinorelbine and carboplatin; VC). Both regimens had a 3-
week cycle, with carboplatin given on day 8 and the other drugs on days 1 and 8. The 
patients went through three cycles. We used vinorelbine in capsule form (oral 
vinorelbine). This allowed comparison with previous studies in Norway that used 
intravenous vinorelbine. We also interviewed patients about how large the treatment 
effect should be to accept treatment.  
The VG combination was no better than VC, in terms of overall survival and health 
related quality of life (HRQoL), and VC remained the preferred regimen for most 
patients.  
Oral vinorelbine had a favourable toxicity profile without compromising survival 
outcomes. Oral vinorelbine have replaced intravenous vinorelbine on day 8, which 
allow for home treatment and simplifying the treatment.  
Studying patients’ attitudes to treatment at the time of diagnosis was complicated. 
This study suggested that most patients accepted the planned treatment even if the 
benefits were minimal.  
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Summary in Norwegian  
Forenkling av lungekreftbehandling – pasient- og behandlerperspektiv 
Lungekreft er den kreftsykdommen som tar flest liv, både i Norge og globalt. Ikke-
småcellet lungekreft er den vanligste typen, og vel halvparten har uhelbredelig 
sykdom ved diagnosetidspunktet. Cellegift kan bremse sykdommen noe, men har 
beskjeden effekt, noe bivirkninger, og krever oppmøte på sykehus for intravenøs 
infusjon. Mindre bivirkninger og enkel gjennomføring av behandlingen er ønskelig. 
Mer kunnskap om hvordan pasientene balanserer nytte og ulemper er også ønskelig.  
Vi gjennomførte en nasjonal studie som sammenliknet en cellegiftkombinasjon med 
noe mindre bivirkninger, vinorelbin-gemcitabin (VG), med den etablerte 
kombinasjonen vinorelbin-karboplatin (VC). Vi brukte vinorelbin i tablettform (oral 
vinorelbin), slik at vi kunne sammenlikne resultatene med tidligere studier i Norge, 
der medisinen ble gitt intravenøst.   
Hovedfunnene er at VC var minst like bra som VG, og brukes derfor fortsatt. Oral 
vinorelbin viste seg like bra som intravenøs, og har forenklet behandlingen.  
Pasientens vurderinger er utfordrende å undersøke på diagnosetidspunktet, som er 
preget av krise og fokus på behandling. Undersøkelsen antyder at pasientene vil takke 




Scientific Environment—the Context of This Work  
My Clinical Practice  
Lung cancer has been the main topic of my clinical work at Haukeland University 
Hospital, Department of Thoracic Medicine, since I started working there in 2001. 
Researching and improving care has always been central to our work and encouraged 
by the leader team.  
The Norwegian Lung Cancer Study Group 
Since 2000, the Norwegian Lung Cancer Study Group (NLCG) has designed and 
carried out several clinical lung cancer studies. These studies have been integrated 
into routine clinical practice and directly influenced clinical practice in nearly all 
departments treating patients with lung cancer. The NLCG board also participated in 
writing the protocol for this study. All physicians in Norway interested in lung cancer 
may join the NLCG. I have contributed actively to the NLCG’s work since 2005. 
Implementation of research results is essential so that the patients can benefit from 
the results. In this realm, an important activity of the NLCG is developing national 
guidelines on the treatment of lung cancer.   
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Lung cancer is the most common cause of cancer death. Most patients with lung 
cancer, 85%, have non-small cell lung cancer (NSCLC) histology. Adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma are the most common subtypes. At 
the time of diagnosis, most patients have an advanced, metastatic or non-curable 
disease [1]. Advanced, metastatic and non-curable disease are overlapping terms. In 
this thesis, I prefer to use the term advanced NSCLC, meaning that the disease is not 
amenable to local treatment (radiation or surgery) with a curative intention. The 
expected lifespan is short as most patients die within a year after diagnosis.  
The Role of Chemotherapy in Advanced Non-Small Cell 
Lung Cancer 
The scientific basis for the use of chemotherapy in advanced NSCLC was established 
in 1995, when a meta-analysis showed a modest effect, with an increase in median 
survival from 4.5 to 6 months [2]. The standard treatment is to offer 3–6 courses in 3-
week cycles with a platinum doublet, commonly either carboplatin or cisplatin 
combined with a so-called third-generation cytotoxic drug, such as vinorelbine, 
gemcitabine, paclitaxel and pemetrexed [1]. The benefits from cytotoxic 
chemotherapy are modest, and side effects such as nausea and immunosuppression 
are common.  
Second-Line Chemotherapy  
After receiving chemotherapy, all patients with advanced NSCLC sooner or later 
experience disease progression and eventually die. Some experience disease 
progression while on treatment, indicating no benefits whatsoever from the treatment, 
while others experience disease progression at some point in time after 
discontinuation of treatment. Second-line treatment refers systemic treatment after 
termination of first-line treatment. The established options for second-line treatment 
are docetaxel [3], erlotinib [4] and, for those with non-squamous histology, 
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pemetrexed [5]. Another option for patients who have responded to treatment is a re-
challenge with the given first-line treatment regimen.  
Pemetrexed Maintenance Chemotherapy 
Maintenance chemotherapy with pemetrexed as an extension of first-line treatment 
can prolong survival in the subgroup of patients with the adenocarcinoma subtype [6, 
7]. However, this treatment does not apply to all patients. Paramount et al. recruited 
patients before the start of first-line treatment and randomised them to pemetrexed 
maintenance treatment, or placebo, after completion of first-line treatment. Only 57% 
were eligible for randomisation [6]. Similar result was found in a Norwegian trial that 
studied late (second-line) vs immediate (maintenance) pemetrexed in advanced non-
squamous NSCLC. In this study, the patients were also recruited before starting their 
first-line treatment, and after first-line treatment, only 45% were eligible for 
randomisation between maintenance treatment and observation (currently 
unpublished data, personal communication, Clinicaltrials.gov NCT02004184). These 
findings indicate that maintenance treatment with pemetrexed is not applicable for 
many patients with advanced NSCLC.  
PD-1/PD-L1 Axis Inhibitors—Immunotherapy 
The results from several phase III trials have confirmed the effectiveness of drugs 
targeting the PD-1/PD-L1 axis (programmed cell death-1 and its ligand PD-L1). Such 
treatment is commonly called immunotherapy. Guidelines recommend a treatment 
course for most patients with advanced NSCLC at some point in time [8]. High PD-
L1 expression in tumour cells is correlated with high response rates but does not 
precisely distinguish between responders and non-responders. Recent studies have 
shown that adding pembrolizumab, a PD-1 inhibitor, to a platinum combination in 
first-line treatment prolongs the survival of NSCLC patients with adenocarcinoma [9] 
and squamous cell carcinoma [10]. Currently, the price of pembrolizumab is an 
obstacle to its use in combination with chemotherapy in Norway. Patients with high 
(>50%) PD-L1 expression in tumours receive pembrolizumab as first-line 
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monotherapy, while other patients with at least 1% PD-L1 expression receive a PD-
1/PD-L1 inhibitor, in accordance with current prices, as second line treatment.  
Bevacizumab 
Adding bevacizumab to platinum-based chemotherapy in selected patients prolongs 
progression-free survival (PFS). The E4599 trial also showed an overall survival (OS) 
benefit; however, it was limited to men [11]. The AVAIL trial confirmed a PFS 
benefit but detected no prolongation of OS [12]. Use of bevacizumab in Norway is 
limited.  
Drugs Targeting ALK/EGFR/ROS1 Alterations 
Patients with tumours harbouring anaplastic lymphoma kinase (ALK) translocation, 
epithelial growth factor receptor (EGFR) mutation or c-ros oncogene 1 (ROS1) 
mutation benefit from treatment with a specific tyrosine kinase inhibitor [8]. Such 
treatment applies only to a minority of patients with advanced NSCLC, 
approximately 10%–15%.  
Patients’ Treatment Preferences 
Evaluation of treatment requires assessing and measuring one or several endpoints. 
This thesis intends focus on endpoints relevant to patients. Poor prognosis is 
prominent in advanced NSCLC. Most patients consider life extension to be their most 
important treatment goal, with health-related quality of life (HRQoL) and avoidance 
of side effects relevant secondary goals [13].  
Life extension means improving OS, which is the time from diagnosis or 
randomisation in clinical trials until death. Survival is also an easily assessed measure 
to monitor the situation in routine clinical practice. In Norway, the Norwegian Cancer 
registry reports the survival of lung cancer patients.  
Several validated instruments are commonly used in cancer trials to assess the 
endpoint of HRQoL, a patient-reported outcome. Measuring HRQoL adds 
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information about the benefits and toxicity of treatment, and HRQoL scores are also 
correlated with prognosis [14, 15]. However, a generally accepted standard of what 
changes and differences in scores are clinically important is lacking [16].  
Rationale for the Studies 
Platinum vs No-Platinum Combination Chemotherapy  
As described, platinum-based doublet chemotherapy is the standard first-line 
treatment for most patients with advanced NSCLC, optionally combined with 
pembrolizumab, if available at lower prices.  
Some studies have suggested the use of non-platinum combinations. For instance, 
Tan et al. found that the combination of vinorelbine and gemcitabine (VG), which is 
less toxic than with the combination of carboplatin and vinorelbine (VC), yields an 
additional 3 months of survival in advanced NSCLC [17]. We found this difference 
surprising, and given that the VC combination is the most commonly used first-line 
treatment for advanced NSCLC in Norway, conformation of the results of Tan et al. 
could promote replacing the VC combination with the less toxic VG combination.  
Oral vinorelbine 
Patients treated with the VC combination receive vinorelbine on days 1 and 8 and 
carboplatin on day 1. Vinorelbine is also available in an oral formulation, which 
allows for home treatment on day 8, saving time for patients and health professionals. 
The use of oral vinorelbine in advanced NSCLC has been outlined and includes 
treatment as a single-agent treatment in with combination chemotherapy and as 
maintenance chemotherapy instead of pemetrexed [18]. Importantly, patients prefer 
the oral vinorelbine formulation [19]. Although the oral vinorelbine formulation is an 
attractive option, data from large, phase III trials are lacking. Using oral vinorelbine 
in a large trial, therefore, could add valuable information about its characteristics.  
Patients’ View on Chemotherapy  
Unfortunately, the benefits from platinum doublet chemotherapy in advanced NSCLC 
are modest, and side effects are common. Treatment decisions in this situation are 
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complex. Patients’ lack of understanding of their own situation raises concerns that 
the decisions may not be shared but, rather, physician controlled [20-23]. 
Surprisingly, no studies have yet been published on how chemotherapy-naïve patients 
with advanced NSCLC view the balance between effect and side effects. If we better 
understood how patients decide their treatment, we might be able to improve the 
communication and decision process in this situation.  
Objectives  
The general aim of this thesis is to simplify treatment for patients with advanced 
NSCLC without compromising the effectiveness. I want to better understand how 
patients balance the benefits and side effects. This goal translates into three questions 
in this thesis:  
1. Can we omit platinum drugs in advanced NSCLC?  
2. Are the outcomes of oral and intravenous vinorelbine similar?  
3. How do chemotherapy-naïve patients with advanced NSCLC weigh the 
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Figure 1. Overview of the patients and papers in the present work. VG = 
vinorelbine and gemcitabine, VC = vinorelbine and carboplatin, IV = 
intravenous, R = randomisation, VING/BLANK = two previous chemotherapy 
trials using vinorelbine and carboplatin.  
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Methods and Subjects 
Study Centres, Patients and Design 
The VG study, which we conducted, was an open, randomised, phase III study. 
Physicians at 35 Norwegian hospitals recruited and treated patients as part of their 
routine practice, so a referral to a study centre was not necessary. For the comparison 
of oral and intravenous vinorelbine, we utilised also data from two earlier advanced 
NSCLC trials (Figure 1).  
Eligible patients in the VG study had NSCLC stage IIIB or stage IV following 
Mountain’s classification (1997; [24] and were not amenable to treatment with 
curative intent. The patients had not previously received chemotherapy for lung 
cancer and underwent a computed tomography scan before enrolment. They had 
performance status (PS) 0–2. Bowel disease affecting absorption of oral vinorelbine 
was an exclusion criterion.  
Randomisation 
Before randomisation, the patients completed the baseline HRQoL form. The 
physicians contacted a central study centre at Haukeland University Hospital (Kontor 
for Klinisk Kreftforskning; KKK) by phone for stratified block randomisation. The 
strata were:  
1. PS 0–1 vs PS 2  
2. Stage IIIB vs stage IV  
3. Age < 75 years vs ≥ 75 years  
Treatment 




o Day 1: Vinorelbine capsules 60 mg/m2 and gemcitabine infusion 1000 mg/m2 
o Day 8: Vinorelbine capsules 60 mg/m2 and gemcitabine infusion 1000 mg/m2 
o Day 22: Cycle no 2  
o Day 43: Cycle no 3  
Gemcitabine and vinorelbine were dosed according to body surface area following 
Dubois and Dubois’s formula [25].  
Regarding gemcitabine and radiation, we required at least 3 days from gemcitabine to 
radiation and at least 2 weeks from radiation to gemcitabine.  
VC  
o Day 1: Vinorelbine capsules 60 mg/m2 and Carboplatin (AUC 5)  
o Day 8: Vinorelbine capsules 60 mg/m2 
o Day 22: Cycle no 2  
o Day 43: Cycle no 3  
We used Calvert’s formula for carboplatin dosing [26] and Cockcroft-Gault’s formula 
to estimate the glomerular filtration rate [27]. 
Dose Adjustments  
The protocol-specified dose adjustments or reasons for delaying a dose were:  
o Patients ≥ 75 years, who received 75% of the full dose  
o Neutropenia or thrombocytopenia  
o Neutropenic infections  
o Other toxicity at the physician’s discretion 
Endpoints and Power Calculations  
OS was the primary endpoint, and the study had, presumed 444 randomised patients, 
80% power to detect an increase in 1-year survival from 29%, as observed in our 
previous studies, to 40%, with a 5% significance level.  
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HRQoL was a secondary endpoint. As in previous NLCG trials, we used the 
European Organization for Research and Treatment of Cancer (EORTC) QlQ-C30 
form and LC13 module for this purpose [28]. The questionnaires are shown in 
Appendix.  
The QlQ-C30 measure symptoms commonly reported by cancer patients, while the 
LC13 module measure symptoms associated with lung cancer.  
The QlQ-C30 have in total 15 scales, nine are multi-item, and six are single-item 
scales (table 1).  The LC13 module have 13 questions and measures symptoms 
commonly associated with lung cancer and its treatment.  
When answering the QLQs, the patients give a score from 1-7 for the two questions 
about global QoL, and from 1-4 on the other questions.  
We pre-specified the following HRQoL analyses: differences between the treatment 
arms in global quality of life and symptom scales for pain, nausea/vomiting, 
dyspnoea and fatigue. The dimension global quality of life at week 9 was the main 
HRQoL endpoint. We calculated that 70 patients in each treatment arm would be 
sufficient to detect differences in mean scores of 11 points or more on scales of 0–
100, with 80% power and 5% significance level. Thus, with 222 patients in each arm, 
the study had the power to detect relevant HRQoL differences.  
Other secondary endpoints were haematological toxicity and the need for palliative 
radiotherapy.  
Assessments and Follow-up 
The patients completed the first HRQoL form before randomisation, every third week 
during treatment (0, 3, 6 and 9 weeks) and every eighth week after treatment (e.g. 17 
and 25 weeks).  
Blood tests were performed weekly during treatment in the local hospitals’ 
laboratories in accordance with local standards and routines.  
We performed no formal response evaluation. Detection of disease progression and 






Data collection on adverse events focused on nausea/vomiting, fatigue, constipation, 
infections, neutropenic fever, blood transfusions and hospitalisations. For each 
chemotherapy cycle, the treating physician completed a form on the treatment 
administered, PS, weight and blood tests.  
 
 
Table 1  Content of the EORTC QLQ-C30 and LC13 questionnaires  
     
QLQ Type of scale Scale    No. of items Question no. 
     
C30 Global health Global QoL  2 29,30  
     
 Functional scales Physical function 5 1-5 
  Role function 2 6,7 
  Emotional function 4 21-24 
  Cognitive function 2 20,25 




 Symptom scales Fatigue 3 10,12,18 
  Nausea, vomiting 2 14,15 
  Pain 2 9,19 
  Dyspnoea 1 8 
  Insomnia 1 11 
  Appetite loss 1 13 
  Constipation 1 16 
  Diarrhoea 1 17 
  Financial difficulties  1 28 
     
LC13 Symptom scales Dyspnoea 3 3-5 
  Coughing  1 1 
  Haemoptysis 1 2 
  Sore mouth  1 6 
  Dysphagia 1 7 
  Periph. neuropathy 1 8 
  Alopecia 1 9 
  Pain in chest 1 10 
  Pain arm or shoulder  1 11 
  Pain in other parts 1 12 
     
The LC13 module also has two questions about the use of pain killers, see appendix.  
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The central study office, KKK, collected all the data, kept the trial database updated 
and sent reminders to clinicians. For each chemotherapy course, the KKK also sent 
the HRQoL forms directly to the patients to be returned to the office. If the forms 
were not returned, the KKK sent one reminder.  
Analyses 
OS analyses followed the intention to treat principle. A Kaplan Meier (KM) plot, log-
rank test and multivariate Cox regression were used.  
We calculated the scores for HRQoL according to the scoring manual [29]. The raw 
scores were transformed to a scale from 0-100.  A high score on functional scales 
means a good function or quality, while a high score on symptom scales means 
severe symptoms. If more than half of the items in a scale were missing, the scale 
score was defined as missing.  We calculated mean scores for every time point and 
tested group differences with the Mann-Whitney U test.  
Toxicity analyses included only the patients receiving at least one treatment cycle, 
and group differences were tested with the Mann-Whitney U test.    
For categorical variables, we used the Chi-square test.  
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Comparison of Oral with Intravenous Vinorelbine 
Oral and intravenous vinorelbine were compared in a retrospective study on three 
study cohorts of patients receiving VC. We pooled data from the VG study (paper 1 
of this thesis) with data from two earlier NLCG trials [30, 31]. The results for the 
patients on oral vinorelbine in the VG study’s VC arm were compared with historic 
results from VC patients on intravenous vinorelbine. The three trials had very similar 
inclusion criteria, used the same instruments and intervals for assessment of HRQoL 
and measured haematological blood tests at the same intervals and time points. The 
main difference was the formulas used for dosing carboplatin. Chatelut’s formula 
with area under the curve (AUC) 4 was used in the two trials with intravenous 
vinorelbine, while Calvert’s formula AUC 5 was used in the VG study with oral 
vinorelbine. We compared OS in a KM plot, using the log rank-test and multivariate 
Cox regression with second-line treatment as a time-varying covariate.  
Haematological toxicity was categorised according to the common terminology 
criteria for adverse events (CTCAE) catalogue, and group differences were tested 
with the Chi-square test. HRQoL was presented with mean scores and mean change 
scores, and we tested group differences with the t-test.  
Patients’ Preferences for Chemotherapy 
The aim of this interview-based study was to explore at what benefit threshold 
patients would chose chemotherapy. We collected data through structured interviews 
using trade-off techniques.  
This research was performed as a sub-study of the VG study at five selected centres. 
The patients were first allocated to their respective treatment regimens in the VG 
study. A trained nurse or physician interviewed the patients on day 1 of the first 
chemotherapy cycle before chemotherapy administration, and on day of the third 
cycle.   
The interviewer used an interactive touchscreen to present information and perform 
the interviews. The questionnaire utilised the time and the probability trade-off 
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techniques [32]. The patients were asked to choose between palliative care (PC) and 
chemotherapy based on the initial assumption that these options could provide equal, 
expected survival outcomes. If the patients chose PC, the expected difference in the 
outcomes of chemotherapy and PC increased in favour of CT until the patients 
switched to CT. This switch indicated the preference threshold for accepting 
chemotherapy.  
The preference threshold for chemotherapy was elicited in four scenarios, two 
exploring thresholds with expected survival expressed in months and two with 
thresholds expressed as the probability of being alive at 12 months.  
For analyses and result presentation, we used descriptive statistics and graphical 
displays of individual responses.  
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Summary of Papers 
First Paper: Non-Platinum Combination in Advanced 
NSCLC  
Objective: We conducted a national, randomised study to compare a non-platinum 
combination and a platinum combination in advanced NSCLC first-line treatment.   
The endpoints were OS, HRQoL, toxicity and use of palliative radiotherapy.  
Results:  We randomised 444 patients from September 2007 to April 2009. The 
median age was 65 years, 58% were men, and 25% had PS 2. Median OS was 6.3 
months for VG and 7.0 months for VC (P 0.802). VC patients had more grade III/IV 
nausea/vomiting (VG: 4%, VC: 12%, P = 0.008) and grade IV neutropenia (VG: 7%, 
VC: 19%, P<0.001). Infections, HRQoL and use of radiotherapy did not differ 
significantly among the treatment groups.  
Conclusion: The two regimens yielded similar OS. The VG combination had only a 
slightly better toxicity profile. The VG study did not undermine the role of a platinum 
combination as the standard first-line treatment for advanced NSCLC.  
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Second Paper: Oral Vinorelbine in Advanced NSCLC  
Objective: We compared outcomes of oral and intravenous vinorelbine, both 
combined with carboplatin as first-line treatment for advanced NSCLC, using data 
from three chemotherapy trials. The end points were OS, HRQoL and haematological 
toxicity.  
Results: A total of 222 and 368 patients received oral or intravenous vinorelbine, 
respectively. The OS (median 7.0 vs. 6.9 months), chemotherapy compliance, 
HRQoL outcomes and toxicity were similar, although oral patients reported less 
worsening of constipation and had fewer adverse events of grade III–IV leukopenia 
and anaemia.  
Conclusion: Oral 60 mg/m² vinorelbine and intravenous 25 mg/m² provided similar 
survival outcomes. The HRQoL outcomes were similar or favoured oral vinorelbine. 
Oral vinorelbine caused less haematological toxicity. The results support the use of 
oral vinorelbine on day 8 in treatment with VC for advanced NSCLC.  
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Third Paper: Patients’ Preferences for Chemotherapy 
Objective: We interviewed chemotherapy naïve patients with advanced NSCLC to 
assess, in terms of life extension, what benefit they would require to accept treatment.    
The study applied both the time trade-off and the probability trade-off techniques.  
Findings: We performed 54 interviews with 30 patients. Half of the patients 
indicated that they required nil benefits to choose chemotherapy. The subjects made 
negligible changes to their answers between the baseline and the interviews after 6 
weeks. The patients and investigators gave anecdotal reports of the difficulties 
concerning the clarity and severity of the prognostic information supplied in the 
questionnaire. 
Conclusion: The majority of the patients would accept chemotherapy for nil or very 
marginal benefits before and after treatment. The topic of patients’ attitudes towards 
toxic chemotherapy is complex, and future studies should focus on these decision 




Discussion of Methods 
Study Setting, Design and Implementation 
The embedding of lung cancer trials in clinical routine practice worked well in 
Norway previously, and together with the wide inclusion criteria, it ensured a low 
threshold for patients with advanced NSCLC to enter the VG study.   
A randomised design is the standard method for excluding systematic errors in 
medical research aiming at comparing efficacy of two treatment regimens. The use of 
stratification avoided an imbalance of certain prognostic factors (strata) in the two 
treatment groups [33]. Randomisation at the central study office eliminated bias in 
the allocation of treatment.  
The open design was more feasible and far less costly than a placebo-controlled 
design. Blinding and a placebo-controlled design have been considered to be relevant 
when using any subjective outcome measures [33]. For the primary endpoint of OS, 
this is not a major concern. Knowledge about treatment regimens could have 
theoretically biased the HRQoL measures. However, a placebo-controlled design 
would have also required hospital visits for all medications, which would have 
precluded home treatment on day 8 in the VC arm. Consequently, the study would 
not have reflected real-life situations. The design soundly balances the trade-off 
between the optimal exclusion of bias and representativeness of real-life situations.  
For comparison of oral and intravenous vinorelbine, the retrospective, non-
randomised design introduced some risk of bias. The study setting and the inclusion 
criteria were similar across the trials, but a competing trial recruited stage IIIB 
patients at the same time as the VG study, affecting the proportion of stage IIIB 
patients [34]. This situation potentially could have introduced a risk that the two 
groups compared had different prognoses, thereby biasing the comparison of interest. 
The retrospective design also introduced a risk that unknown confounding factors 
might bias the comparison.  
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Treatment 
Several formulas for carboplatin dosing exist, and most account for renal function 
[27, 35]. Measuring the creatinine clearance with radionuclide methods is difficult in 
everyday oncology practice, and using serum creatinine level for calculating renal 
function is regarded acceptable. Calvert’s formula is one the commonly used 
formulas for this purpose [36]. The carboplatin dosing with Calvert’s formula and 
AUC 5 corresponds to Chatelut’s formula with AUC 4, which was used with 
intravenous vinorelbine in the two trials, but entails a higher carboplatin dose in 
women and a lower dose in men (author’s calculations). This difference in 
carboplatin dosing introduces a potential bias towards more leukopenia and anaemia 
in women on oral vinorelbine and justifies subgroup analyses to explore toxicity 
related to the two formulations.  
The 60 mg/m2 dosing of oral vinorelbine correspond to the intravenous 25 mg/m2 
dose [37], which we used in previous trials [30, 31]. The gemcitabine dosing was in 
line with practice in combination chemotherapy [17, 31].  
The 25% dose reduction in elderly patients ≥ 75 years old has been standard practice 
in both trials and clinical practice in Norway. Its scientific foundation can be 
questioned, though, as Calvert’s formula already accounts for age [38]. Overall, the 
treatment procedures in the studies were in line with clinical routine practice and did 
not complicate participation in the trial.  
End Points  
OS and HRQoL reflect what the patients regard as the most important attributes of 
therapy [39]. OS is considered to be an easily and precisely measured and reliable 
end point in clinical trial, based on objective assessments. A limitation of OS as an 
endpoint is that it is influenced not only by the study treatment but also by any 
treatment administered after the study treatment (second-line treatment). 
An alternative to OS, progression-free survival (PFS), is a composite endpoint used in 
many clinical oncology trials today and is commonly reported as the primary 
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endpoint. PFS is a reasonable endpoint if treatment after the study treatment 
substantially affects OS. Second-line treatments are increasingly used. In this project, 
PFS could have added valuable information, especially in the comparison of oral and 
intravenous vinorelbine. However, regularly response assessment with computer 
tomography after treatment was not a standard procedure at the time of the VG study 
and would have added substantial costs to the study.  
The EORTC QLQ-C30 and LC 13 questionnaires have been used in several lung 
cancer trials in Norway. Delivering the HRQoL forms by mail to the participants has 
worked well previously and ensured standardised instructions to all the participants. 
The validity and reliability of these instruments has been reported elsewhere [40], and 
we regarded these instruments as good indicators of the patients’ situation during and 
shortly after the treatment period. However, the wording of the questionnaire items 
directed the respondents’ attention to experiences during the preceding week, not the 
entire 3-week chemotherapy cycle. The timing and number of assessments could 
influence the likelihood of detecting differences in HRQoL during chemotherapy, and 
day 4 in the chemotherapy cycle has been proposed as the best time point for 
assessing alterations in HRQoL [41]. Delivering the forms every third week was a 
compromise between the patients’ workload and the additional information gained at 
the risk that transient substantial side effects would go undetected.  
The HRQoL information gathered after the treatment period probably had little value, 
and the information gathered after 17 weeks, in particular, probably added no 
substantial information about the situation during the chemotherapy period. 
In the toxicity comparison in paper 2, only haematological toxicity was compared as 
data on other adverse events (AE) were not collected uniformly across the three trials. 
Bioavailability studies could have been valuable to highlight the comparison of 
formulations but were beyond the scope of the VG study.  
Patients’ Perspectives 
The lack of research standards in this field is challenging, and the contextual situation 
could influenced bias in the answers. The patients had already decided to receive 
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chemotherapy in the chemotherapy trial. We did not assess their knowledge about 
their situation or systematically inform them about their prognosis before the 
interviews. The patients’ lack of familiarity with the situation was also obvious. A 
strength of the study was the performance of two interviews, which enabled 
observing whether the responses changed during treatment. The study design was 
exploratory, which the interpretation of the findings needed to reflect.  
Statistical Analyses 
The survival analyses followed the intention to treat principle with standard test 
methods. Sub-group analyses were relevant for age groups < 75 and ≥ 75 years, 
according to the practice of dose reduction in the elderly. For comparison of oral and 
intravenous vinorelbine, multivariate Cox regression analysis was helpful to adjust 
for confounders. Adjustment for the use of second-line treatment, a time-varying 
covariate, is problematic as use of second-line treatment is itself a marker of 
worsening of the disease. However, assuming equal distribution of disease 
progression in the two arms, the use of this time-dependent covariate adjusted for 
differences in the use of second-line treatment.  
Regarding the HRQoL analyses, analyses of mean scores and mean changes since 
baseline have been criticised [42] as they risk not detecting small differences. Time to 
deterioration, area under the curve, and linear mixed models for longitudinal data 
have been proposed methods. Osoba et.al have advocated for a simpler approach, 
including analyses of mean scores and mean changes [43]. We also used different test 
methods (Mann Whitney U test and t-test) in paper 1 and paper 2. In general, 
agreement on and standardisations of how to analyse and present HRQoL analyses in 
clinical cancer trials are lacking. More importantly, our study samples were 
sufficiently large to detect the predefined clinically relevant group differences of 11 
points.  
Regarding haematological toxicity, the use of data only from patients who had 
received at least one chemotherapy course seems to have been appropriate. The use of 
different test methods (the Mann-Whitney U test in paper 1, and the categorisation of 
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the CTCAE catalogue and Chi-square test in paper 2) probably have minor 
importance.  
Reliability 
Reliability refers to the consistency of a measure, or the reproducibility of a 
measurement when repeated at random in the same subject or specimen [44]. Time of 
death and OS are probably not subject to systematic bias, and if most subjects are 
observed until death (few censures); OS will also be a highly reliable measure of 
survival in the sample.  
For the HRQoL end point, the reliability of the EORTC QlQ-C30 and LC13 module 
has been confirmed, with the exception of the dimension of cognitive functioning 
[40]. Regarding haematological toxicity, we assumed that the laboratories at the local 
hospitals provided services of satisfactory quality and reliability for the purpose of 
this study and in line with the accepted standards.  
In the study on the patients’ perspectives, the reliability of this test procedure has not 
been evaluated in the actual context.  
Internal Validity 
Internal validity concerns the conclusions within the study context and means that the 
observed differences between groups are related to the intervention tested [45]. The 
high internal validity of the randomised VG study was indicated by the randomised 
design, relevant statistical analyses, use of relevant, reliable, predefined endpoints, 
adequate powering of study and the process to ensure the completeness of the data.  
Regarding the HRQoL measures, the sample size was larger than needed to detect 
clinically meaningful differences. Data attrition, which is inevitably in advanced 
cancer trials, however, can threaten the validity. If the survival or the complication 
rates are different at a time point when HRQoL assessment, this will complicate the 
interpretation of HRQoL analyses.  
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Regarding the comparison of oral and intravenous vinorelbine, the retrospective, non-
randomised design is a relevant weakness and has the potential to bias the analyses 
and thereby affect internal validity. The statistical methods cannot fully account for 
this possibility, so interpretation of the results must take into account these 
challenges.  
Regarding the patients’ perspectives, the internal validity of paper 3 is difficult to 
evaluate due to the lack of standardisation of research methods in this research field.  
External Validity  
External validity refers to the usefulness of results outside the study context. The 
result must be relevant outside the trial to the group they are supposed to represent, 
and the end points must be clinically relevant [46]. The study setting, wide selection 
criteria, relevant endpoints and representation of an everyday routine practice are 
were relevant to clinical routine practice and are indicators of external validity. 
Regarding paper 3, however, one should keep in mind that the interview situation 
differed significantly from routine practice, and the arguments for external validity 
are questionable.   
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Discussion of the Main Results 
Main Findings 
The VG study, a randomised, phase III trial conducted in routine lung oncology 
practice in Norway, did not confirm the superiority of VG over VC for patients with 
advanced NSCLC (paper 1).  
In the study, oral vinorelbine was administered, and the comparison with intravenous 
vinorelbine, used in two previous trials, indicated that oral vinorelbine yielded similar 
OS and HRQoL outcomes. Some HRQoL scales and haematology analyses indicated 
less toxicity than the oral formulation (paper 2).  
In a subset of the patients, interviewed before start of treatment about their 
preferences, most of them would accept to receive chemotherapy for a very low or nil 
benefit threshold (paper 3).  
The strength of the VG study relates to being conducted in routine clinical practice, 
as were also our previous trials [47, 48]. The accrual time of the VG study was a little 
longer, 19 months instead of 15 months. The difference partly results from inclusion 
of a smaller proportion of stage IIIB patients due to a competing trial [34]. We 
estimated that 31% of Norwegian patients with stage IV NSCLC entered the trial 
during the recruitment period. The VG study thus recruited a large proportion of the 
patient population, and hopefully, this large proportion was representative of that 
population.  
The median survival of 7 months and the hospitalisation of 44% of the patients during 
the treatment period reflects the poor prognosis and high disease burden in this 
patient group.  
Our findings of similar OS for VC and VG differed from Tan et al., who reported a 
superior OS of 11.5 months in the VG arm compared to 8.6 months with VC [17]. 
Some differences in the study design are notable. We included older patients (median 
65 years old vs 60 years old) and allowed inclusion of patients with PS 2 and brain 
metastases. We administered a fixed treatment regimen of three cycles. Tan et.al 
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administered up to six cycles depending on the response. They also administered a 
higher vinorelbine dose of 30 mg/m2 in the VC arm. None of these differences, 
though, can explain that we could not confirm the superiority of VG over VC. 
However, our practice of dose reduction in the elderly lacks scientific support, and 
the finding (post-hoc analyses) of the elderly patients in the VG arm who had inferior 
OS with VG could indicate less than optimal drug exposure in elderly VG patients.  
The HRQoL results in both papers 1 and 2 should be interpreted cautiously. We 
observed a decline in the questionnaire completion rate from 100% at baseline to 
80% at weeks, indicating modest data attrition. In the randomised VG study, the 
detected differences in the groups’ HRQoL scores were small, far less than the pre-
defined threshold of 11 points. The completion rates of the two groups were similar, 
making it less likely that a significant difference was not detected, although it cannot 
be ruled out [49].  
In the comparison of oral and intravenous vinorelbine in paper 2, one should also take 
into account that multiple scales were tested, which increased the risk of, by chance, 
observing differences that were not true. The differences in the scales constipation 
(during treatment), peripheral neuropathy and alopecia, however, consistently 
favoured oral vinorelbine. A reasonable interpretation is that it supports that oral 
vinorelbine 60 mg/m2 is less toxic than intravenous 25 mg/m2, , as shown in the 
analyses of haematological toxicity.      
A plausible explanation for the lesser toxicity of oral vinorelbine is the lower and 
slower achievement of a peak concentration of vinorelbine [50, 51]. Another possible 
explanation is that the assumption of similar drug exposure with oral 60/m2 and IV 
25/m2 is not entirely true. Bias from different carboplatin dosing is not a likely 
explanation as women with higher carboplatin doses under Calvert’s formula with 
AUC 5 had less haematological toxicity than with the oral formulation. The 
methodological challenges in this study, therefore, do not undermine the main finding 
of less toxicity with oral vinorelbine 60 mg/m2 than intravenous 25 mg/m2.  
Interpretation of the findings on the patients’ preferences is not straightforward. The 
patients’ lack of familiarity with the situation shortly after receiving their diagnosis 
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and the complexity of studying this question is challenging. Given that the expected 
benefits of systemic first-line treatment today are better than the threshold our 
patients reported, a pragmatic approach is to conduct further studies in this field later 
in the disease course (i.e. the second-line situation).  
Implications and Implementation 
The favourable toxicity profile of the VG regimen could support its use. However, 
the VG study had a superiority design, so we cannot conclude that VG is non-inferior 
to VC. The minor toxicity and HRQoL differences in favour of VG do not justify 
changing from a platinum regimen to a non-platinum regimen.  
The oral formulation received marketing approval shortly before the VG trial, and the 
trial was itself instrumental in implementing oral vinorelbine for advanced NSCLC. 
Today, most patients in Norway receive the oral form on day 8 in the 3-week VC 
cycle (personal communication). This approach enables home treatment, but most 
centres still practice hemogram on day 8, which requires a visit to a medical facility. 
A trial with cisplatin and vinorelbine showed that omitting day 8 hemogram is safe 
[52], but whether this omitting is safe also in the VC combination is not clear. 
Nevertheless, oral vinorelbine saves some time for hospital staff and ‘needle’ and 
waiting time for patients, and it avoids phlebitis from vinorelbine.  
Future Perspectives 
The prognosis for patients with advanced NSCLC has improved substantially in the 
past decade due to treatments other than chemotherapy. This improvement applies 
both to the minority of patients with tumours with EGFR, ALK and ROS1 mutations 
and to the large remaining group of patients, who very clearly benefit from the drug 
group affecting the PD-1/PD-L1 axis. Recent milestone studies on pembrolizumab 
have clearly demonstrated the benefits of its implementation in first-line treatment [9, 
10, 53]. Patients with > 50% PD-L1-positive tumours benefit from pembrolizumab 
monotherapy, and other patients with non-squamous cell histology benefit from a 
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combination of carboplatin-pemetrexed-pembrolizumab and from pemetrexed-
pembrolizumab as maintenance treatment, while patients with squamous cell 
histology benefit from the combination of pembrolizumab with carboplatin and 
paclitaxel and from pembrolizumab as mono-maintenance  
These encouraging first-line trials with pembrolizumab and chemotherapy did not 
include vinorelbine, so its future role in advanced NSCLC necessitates further 
research. One aspect in this field is that effective first-line treatment now requires 
multiple infusions. Patients receive maintenance treatment with a PD-1 inhibitor 
every third week for up to 35 cycles, and patients with adenocarcinoma also receive 
pemetrexed. A previous study conducted before the PD-1-inhibitor era suggested oral 
vinorelbine instead of pemetrexed in maintenance treatment [54]. If an oral PD-1/PD-
L1 inhibitor could replace pembrolizumab, a combination with oral vinorelbine, 
instead of pemetrexed, could replace a huge number of infusions. However, it is not 
clear whether an oral PD-1-inhibitor will be available in the future [55].  
Another question concerning oral vinorelbine is its potential role as a second-line 
treatment. Until recently, the main second-line options were docetaxel, erlotinib, and 
PD-1/PD-L1 axis inhibitors, and for patients with the adenocarcinoma subtype, 
pemetrexed. Pemetrexed and PD-1-PD-L1 axis inhibitors, as shown for 
pembrolizumab, have become first-line treatments, leaving docetaxel and erlotinib as 
second-line treatments. National guidelines in Norway do not recommend erlotinib 
for EGFR-negative patients, and clinical experiences with docetaxel in second-line 
treatments are not encouraging. Further, docetaxel’s role as a post-immunotherapy 
drug is not yet clear. Consequently, we lack scientific evidence for an optimal 
second-line treatment strategy for a very large group of patients with advanced 
NSCLC. Whether vinorelbine will play a role as a second-line treatment for advanced 
NSCLC, either as a monotherapy or in combination with other agents, is not clear. 
However, if used as a monotherapy in second-line chemotherapy, it probably will 
have rather limited effects, so its use will be limited.  
Patients’ perspectives on benefit thresholds for accepting toxic treatment are also 
highly relevant in this regard.  
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Conclusions 
1. The VG study confirms the role of a platinum combination as the main 
treatment in first-line treatment of advanced NSCLC.  
2. The future role of vinorelbine in the treatment of advanced NSCLC is 
currently unclear.  
3. When combined with carboplatin, the oral formulation of vinorelbine can be 
preferred, at least on day 8 in the 3-week cycle.   
4. Patient’s benefit thresholds for accepting treatment should be elicited before 
second-line chemotherapy for advanced NSCLC 
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Vinorelbine and gemcitabine vs vinorelbine and carboplatin as
first-line treatment of advanced NSCLC. A phase III randomised
controlled trial by the Norwegian Lung Cancer Study Group
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BACKGROUND: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer
(NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We
conducted a national, randomised study to compare a non-platinum with a platinum combination.
METHODS: Eligible patients had stage IIIB/IV NSCLC and performance status (PS) 0–2. Patients received up to three cycles of
vinorelbine 60mgm 2 p.o.þ gemcitabine 1000mgm 2 i.v. day 1 and 8 (VG) or vinorelbine 60mgm 2 p.o. day 1 and
8þ carboplatin area under the curve¼ 5 (Calvert’s formula) i.v. day 1 (VC). Patients X75 years received 75% of the dose. Endpoints
were overall survival, health-related quality of life (HRQoL), toxicity, and the use of radiotherapy.
RESULTS: We randomised 444 patients from September 2007 to April 2009. The median age was 65 years, 58% were men and 25%
had PS 2. Median survival was VG: 6.3 months; VC: 7.0 months, P¼ 0.802. Vinorelbine plus carboplatin patients had more grade III/IV
nausea/vomiting (VG: 4%, VC: 12%, P¼ 0.008) and grade IV neutropenia (VG: 7%, VC: 19%, Po0.001). Infections, HRQoL and the
use of radiotherapy did not differ significantly between the treatment groups.
CONCLUSION: The two regimens yielded similar overall survival. The VG combination had only a slightly better toxicity profile.
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The ideal palliative cancer therapy is effective, harmless and easy
to administer. Platinum-based combination chemotherapy is
regarded as the standard in first-line therapy in the majority of
patients with advanced non-small cell lung cancer (NSCLC).
However, benefits in terms of prolonged survival and symptom
relief are modest, whereas side effects are common, even when
carboplatin is chosen over cisplatin for its favourable toxicity
profile (Azzoli et al, 2009; Goffin et al, 2010). Thus, searching for
alternative regimens that might improve health-related quality of
life (HRQoL) while maintaining efficacy, is still warranted. An
approach is to combine two of the modern third generation non-
platinum agents, such as docetaxel, paclitaxel, pemetrexed,
vinorelbine, or gemcitabine.
Several randomised controlled trials have compared a platinum
combination with vinorelbine and gemcitabine (VG) (Laack et al,
2004; Zhang et al, 2004; Barlesi and Pujol, 2005; Lilenbaum et al,
2005; Tan et al, 2005; Yamamoto et al, 2006; Greco et al, 2007; Han
et al, 2008; Kubota et al, 2008). Most of these studies demonstrated
that VG is as effective but less toxic than the respective platinum
combinations. One study (Tan et al, 2005), however, compared VG
with vinorelbine plus carboplatin (VC), both regimens adminis-
tered in a 3-week schedule to a maximum of six cycles. They found
superior survival of 3 months and a more favourable toxicity
profile for the VG combination.
As a response to the improved survival by VG over VC
presented by Tan et al (2005), the Norwegian Lung Cancer Study
Group designed a randomised study comparing VG with VC as a
first-line treatment in patients with advanced NSCLC. We chose
to administer three cycles of chemotherapy, based on the results
of three randomised studies assessing the length of therapy
in advanced NSCLC (Smith et al, 2001; Socinski et al, 2002;
*Correspondence: Dr Ø Fløtten; E-mail: oystein.flotten@gmail.com
Received 27 January 2012; revised 17 May 2012; accepted 30 May 2012;
published online 3 July 2012
British Journal of Cancer (2012) 107, 442–447












von Plessen et al, 2006). Further, we chose oral vinorelbine
for both treatment arms because of convenient administration,
patient preferences, and a similar safety profile as the intravenous
formulation (Vokes et al, 1994; Liu et al, 1997; Jassem et al, 2001;
Marty et al, 2001; Jassem et al, 2003; O’Brien et al, 2004; Jensen
et al, 2008).
The primary aim of the study was whether VG is superior to VC
with respect to overall survival. Secondary aims were to compare
HRQoL, toxicity, and the use of palliative radiotherapy.
PATIENTS AND METHODS
Design and approval
The study was an open, randomised, multicenter phase III trial.
It was approved by the Regional Committee for Medical Research
Ethics, Western Norway, the Norwegian Social Science Data
Services, and the Norwegian Medicines Agency.
Eligibility criteria
Eligible patients had NSCLC stage IV or stage IIIB not eligible for
curative treatment, and WHO performance status (PS) 0–2.
Patients had to have adequate bone marrow and liver function,
no other active malignancy and no gastrointestinal disease
affecting absorption of vinorelbine. We allowed inclusion of
patients with brain metastases, and defined no upper age limit.
Randomisation
After the patients had signed the informed consent form and
completed the baseline HRQoL form, they were randomised by
phone to the central study office at Haukeland University Hospital,
Bergen, Norway. Randomisation was stratified by WHO PS 0–1 vs 2,
stage IIIB vs IV and age o75 vs X75 years.
Chemotherapy
Both groups were planned for three cycles of chemotherapy in 3-week
cycles. Vinorelbine and gemcitabine patients received vinorelbine
capsules 60mgm 2 plus intravenous gemcitabine 1000mgm 2,
on days 1 and 8. Vinorelbine plus carboplatin patients received
carboplatin according to area under the curve¼ 5 (Calvert’s formula)
on day 1 plus vinorelbine capsules 60mgm 2 on days 1 and 8.
The oral dose of vinorelbine 60mgm 2 is comparable with the
commonly used intravenous dose of 25mgm 2 (Marty et al, 2001).
Patients 75 years and older had their doses reduced by 25%. Both
groups received prophylactic antiemetics with an intravenous
glucocorticoid and 5-HT3-antagonist on day 1, the VG patients also
on day 8. Vinorelbine plus carboplatin patients received an oral
5-HT3-antagonist b.i.d. on day 8.
Before the start of each cycle, the absolute neutrophil count
(ANC) had to be X1.0 109 l 1 and platelets X75 109 l 1. The
doses were reduced by 25% if ANC was 1.0–1.49 109 l 1, platelets
were 75–99 109 l 1, or preceding nadir ANC was o0.5 109 l 1.
Doses were reduced by 50% if the nadir platelet count was
o50 109 l 1. All dose reductions were maintained for subsequent
cycles. Chemotherapy was discontinued if a cycle was delayed by
more than 21 days. In cases of neutropenic infections or other
grade 3–4 toxicity, chemotherapy was postponed until clinical and
haematological recovery and all remaining doses were reduced
by 25%. Disease progression, unacceptable toxicity or a patient’s
request were reasons for discontinuation of the study treatment.
Patient follow-up
All patients underwent a chest X-ray and a CT scan of thorax and
upper abdomen before randomisation. Patients were examined
clinically and weighed at the start of each treatment cycle.
Laboratory tests were performed weekly throughout the treatment
period. A chest x-ray was performed at week 9 and every 8 weeks
thereafter. Further imaging to determine the disease progression
was performed at the treating physician’s discretion.
Endpoints
The primary endpoint was overall survival. The secondary
endpoints were HRQoL, toxicity and the use of palliative radio-
therapy. The prespecified HRQoL analyses were differences
between the treatment arms in global QoL and symptom scales
for pain, nausea/vomiting, dyspnoea, and fatigue. We defined
global QoL at week 9 as the primary HRQoL-endpoint. The study
was not designed to assess response rates or time to progression.
Assessment of HRQoL
The patients reported HRQoL on the European Organisation for
Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire QLQ-C30 and its lung cancer-specific module LC13
(Aaronson et al, 1993). The QLQ-C30 measures fundamental
aspects of HRQoL and symptoms commonly reported by cancer
patients, whereas the LC13 measures symptoms commonly
associated with lung cancer and its treatment. Baseline HRQoL
questionnaires had to be completed before randomisation. Follow-
up questionnaires were mailed from the study office to the
patients’ home addresses and were completed immediately before
each cycle, 3 weeks after the last cycle, and then every 8 weeks until
57 weeks after the start of treatment. Patients returned the
completed forms to the study office in a pre-stamped envelope.
Non-responders received one reminder by mail after 14 days.
Statistical considerations
We needed 444 patients to detect an increase in 1-year survival
from 29 to 40% with 80% power at a 5% significance level,
assuming an accrual time of 52 weeks and a minimum follow-up
time of 52 weeks. We used the function cpower in Frank Harrell’s
Hmisc package for R for power calculations (Harrell, 2003). We
defined survival time as the time from randomisation until death,
and compared the treatment groups with the Kaplan–Meier
method and the log-rank test.
Health-related quality of life scores were calculated according to
the EORTC QLQ-C30 Scoring Manual (Fayers et al, 2001). A high
global health status QoL score represents a good QoL, whereas a
high symptom-scale score represents more symptoms. Mean
scores were calculated for reported values only and compared
between the two groups using the Mann–Whitney U-test. We
considered a difference in the mean score of 410 points as
clinically relevant. Toxicity was categorised according to the
Common Terminology Criteria for Adverse Events (CTCAE) v3.0
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/
docs/ctcaev3.pdf). The Mann–Whitney U-test was used for group
comparisons of haematological toxicity. For analyses of other adverse
events and the need for palliative radiotherapy, the w2 test was used.
The level of significance was defined as Po0.05.
RESULTS
Patients
Between September 2007 and April 2009, 444 patients from 35
Norwegian hospitals were randomised. Seven patients were
excluded from all analyses; six because of ineligibility, and one
because of administration of the wrong study therapy. Three
patients did not receive any study treatment (Figure 1). The
analysed patients had, VG vs VC respectively, a median age of 65 vs
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65 years, 41% vs 43% had female gender, 26% vs 25% had PS level 2,
85% vs 85% had disease stage IV, 55% vs 59% had adenocarcinoma,
and 5% vs 7% were never smokers (Table 1). We analysed 437
patients for survival, HRQoL and use of palliative radiotherapy,
and 434 for toxicity. The survival analysis was finalised in May
2011 after 416 patients had died.
Chemotherapy
The mean number of chemotherapy cycles was (VG vs VC,
respectively) 2.6 vs 2.7, while patients X75 years received 2.3 vs
2.7 cycles. The number of patients receiving three cycles without
dose reduction was 127 (59%) vs 128 (58%). Study therapy was
discontinued due to toxicity in 9 (4%) vs 7 (3%) patients, and due to
progressive disease in 24 (11%) vs 25 (11%) patients. Study therapy
on day 8 was omitted in 44 of 551 (8%) vs 37 of 593 (6%) cycles.
Overall survival
Overall survival did not differ significantly between the two
treatment groups (Figure 2). The median survival time was 6.3 vs
7.0 months (HR¼ 1.025, CI¼ 0.85–1.24; P¼ 0.802), with a
corresponding 1-year survival rate of 30% vs 27% in the VG and
VC arms, respectively.
Good PS and disease stage III were associated with a better
prognosis. Median survival was 12.2, 6.8, and 4.3 months for PS
0, 1, and 2, respectively, (Po0.001). Median survival was 9.0, 10.4,
and 6.3 months for stage IIIBdry, stage IIIBwet, and stage IV,
respectively (P¼ 0.036).
Post-hoc subgroup analyses showed that among patients X75
years (n¼ 74) VG patients had an inferior median survival of 4.6 vs
8.0 months for the VC patients (HR¼ 1.70, CI¼ 1.05–2.73;
P¼ 0.028), and a corresponding 1-year survival rate of 18% vs
28%. This difference was, however, not statistically significant in a
multivariate analysis adjusting for PS level and stage of disease
(HR¼ 1.55, CI¼ 0.95–2.53). We found no differences in median
survival between the treatment arms for patients o75 years (VG:
6.9 months, VC: 6.8 months; HR¼ 0.89, CI¼ 0.72–1.10; P¼ 0.296).
Age itself was not found to be a significant prognostic factor (o75
years: 6.9 months, X75 years: 6.2 months, P¼ 0.066). Neither did
multivariate analysis with interaction test reveal any significant
association between age and survival.
We observed no significant differences between treatment arms
(VG vs VC, respectively) at any PS level (PS 0: 12.6 vs 11.4 months,
P¼ 0.208; PS 1: 6.5 vs 7.0 months, P¼ 0.835; PS 2: 4.0 vs 4.5
months, P¼ 0.418) or stage of disease (IIIBdry: 11.3 vs 7.5 months,
P¼ 0.446; IIIBwet: 7.6 vs 10.8 months, P¼ 0.913; IV: 6.2 vs 6.7
months, P¼ 0.924). Neither did we find any significant association
between survival and gender, histology or smoking history (data
not shown).
Health-related quality of life
Alive patients completed, VG and VC, respectively, 89% (850
forms) and 90% (910 forms), of the expected HRQoL
Ineligible patients   n = 1 
   Never signed consent n = 1 
Randomised 




n = 223 
No study treatment   n = 2 
   Patients wish    n = 1 
   Unfit for gemcitabine due to radiotherapy  n = 1 
No study treatment   n = 1 
   Intercurrent disease   n = 1 
Analysed  
   Survival, palliative radiotherapy, HRQoL  n = 215 
   Toxicity    n = 213 
Analysed  
   Survival, palliative radiotherapy, HRQoL  n = 222 
   Toxicity    n = 221 
Ineligible patients  n = 6 
   Never signed consent n = 2 
   Revised diagnosis  n = 3 
   Wrong study treatment 
administered n = 1
Figure 1 CONSORT diagram.









X75 years 38 18 36 16
Gender
Male 126 59 126 57
Female 89 41 96 43
WHO performance status
PS 0 48 22 47 21
PS 1 112 52 119 54
PS 2 55 26 56 25
Stage (Mountain 1997)
IIIBdry 23 11 20 9
IIIBwet 9 4 14 6
IV 183 85 188 85
Histology
Squamous cell carcinoma 55 26 45 20
Adenocarcinoma 118 55 131 59
Large cell carcinoma 9 4 12 5
Other/undifferentiated 33 15 34 15
Smoking history
Never smoker 11 5 15 7
Former smoker 114 53 129 58
Smoker 90 42 77 35
Abbreviations: VC¼ vinorelbine plus carboplatin; VG¼ vinorelbine and gemcitabine.
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questionnaires during the first 17 weeks. The results of pre-
specified HRQoL analyses are summarised in Table 2. Vinorelbine
plus carboplatin patients had a statistically significantly higher
mean score for nausea/vomiting at week 3 (P¼ 0.028) and week 6
(P¼ 0.012), but the difference was only four points. We observed
no significant differences between treatment arms after week 17,
and neither did other scales or items differ consistently between
treatment arms.
Toxicity
Haematological toxicity, adverse events, and hospital admissions
are summarised in Table 3. Fewer patients in the VG arm
experienced grade 4 neutropenia (VG: 7%; VC: 19%; Po0.001). We
found no corresponding difference in the number of patients
experiencing febrile neutropenia (VG: 4%; VC: 8%; P¼ 0.127), or
other grade 3 or grade 4 infections over all (VG: 20%, VC: 18%;
P¼ 0.517). Fewer VG patients experienced grade 3 or grade 4
nausea/vomiting (VG: 4%; VC: 12%; P¼ 0.008). More VC patients
received blood transfusions, but the difference was not statistically
significant (VG: 10%; VC: 16%; P¼ 0.092).
Post-study therapy
The use of palliative radiotherapy did not differ between the
treatment arms as 101 (47%) VG patients and 111 (50%) VC
patients received palliative radiotherapy (P¼ 0.497).
Ninety-one (42%) VG patients and 97 (44%) VC patients
received at least one systemic second-line therapy (P¼ 0.773). The
most common regimens were (VG vs VC) erlotinib (25% vs 27%),
pemetrexed (17% vs 15%), and carboplatin-doublets (19% vs 9%).
The use of systemic second-line therapy was associated with a
better PS level (PS 0: 72%; PS 1: 39%; PS 2: 27%; Po0.001) and low
age (o75 years: 46%; X75 years: 27%; P¼ 0.003).
DISCUSSION
In this randomised trial we did not observe any difference in
overall survival between VG and VC as first-line chemotherapy of
advanced NSCLC. Thus, we could not confirm the results from Tan
et al’s (2005) study where VG was found superior to VC. Our
results corroborate a meta-analysis that demonstrated similar
survival between carboplatin-based doublets and modern non-
platinum doublets (Rajeswaran et al, 2008).
During the inclusion period of this study, 1185 individuals in
Norway were diagnosed with NSCLC stage IV, whereas the number
of stage IIIB patients, specifically, could not be assessed
(Norwegian Cancer Registry, personal communication). Hence,
the 371 stage IV patients enrolled in this study constituted 31% of
these patients nationwide during the period, suggesting this study
to be representative for the Norwegian population of patients with
advanced NSCLC.
We chose an open-study design to facilitate participation of lung
cancer centres of all sizes in this national study. The open design
could possibly bias the HRQoL reporting. On the other hand, a
blinded study’s drawback would be the necessity of a placebo
infusion on day 8 in the VC arm, and thereby not reflecting the real
clinical practice.
The median survival time was relatively short in both the
treatment arms, only 6.3 and 7.0 months for patients in the VG and
VC arms, respectively. This survival is lower than the 11.5 and 8.6
months in the study by Tan et al (2005). While the median age in
their study was 60 years, it was 65 years in ours. They included
patients with only Karnofsky PS level of 80–100 points, which
approximates WHO PS level 0–1 (Buccheri et al, 1996), while we
included 25% PS 2 patients. Tan et al (2005) did not include
patients with brain metastases, which was allowed in the present
study. The inclusion of patients with dissimilar important
prognostic factors is a plausible explanation for the survival
difference between these two studies.
The choice of carboplatin instead of cisplatin is a factor that
could have influenced survival negatively in this study. The debate
Table 2 Completion rates of the HRQoL questionnaires and mean scores for the primary HRQoL outcomes
Baseline 3 weeks 6 weeks 9 weeks 17 weeks Total
VG VC VG VC VG VC VG VC VG VC VG VC
No. of patients alive 215 222 206 219 198 211 184 202 144 165 947 1019
No. of delivered forms 215 222 194 207 169 189 152 161 117 130 847 909
Completion rate (%) 100 100 94 95 85 90 83 80 81 79 89 88
Global QoL 55 55 54 54 54 55 53 55 53 54
Nausea and vomiting 12 11 12 16* 13 17* 12 15 11 12
Dyspnoea LC13 38 40 39 40 38 36 37 33 41 37
Pain C30 31 35 30 33 30 31 31 31 31 32
Fatigue 47 48 50 50 51 48 49 48 48 47
Abbreviations: HRQoL¼Health-related quality of life; VC¼ vinorelbine plus carboplatin; VG¼ vinorelbine and gemcitabine. All scale scores range from 0 to 100. A high global
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Figure 2 Kaplan–Meier survival plots according to the treatment arms.
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on cisplatin vs carboplatin is beyond the scope of this paper, but
we note that the updated ASCO guideline state carboplatin as an
acceptable option in advanced NSCLC, despite a small survival
disadvantage (Azzoli et al, 2011).
Another question is whether the administration of only three
chemotherapy cycles (as compared with four to six cycles
recommended in guidelines) has influenced the survival nega-
tively. A Scandinavian study showed that a six-cycle schedule is
not significantly better than three cycles (von Plessen et al, 2006).
Further, in another Norwegian study from our group, the four-
cycle schedule of carboplatin and pemetrexed yielded a similar
survival of 7.3 months (Gronberg et al, 2009). This suggests that a
negative survival contribution from the short treatment length is of
only minor significance in this study.
The current study offered combination chemotherapy to both
elderly patients and PS 2 patients, while current NSCLC guidelines
suggest the use of single-agent therapy in these groups (D’Addario
et al, 2010). The trend towards a favourable survival of 8.0 months
with VC in the elderly patients suggests that this regimen, with a
25% dose reduction, is an acceptable option. However, the poor 4.3
months median survival in PS 2 patients questions the use of toxic
and time-consuming combination chemotherapy.
The use of systemic second-line therapy in only 43% of patients
may have negatively affected the survival in this study. In selected
populations of some clinical trials as many as 67% of the patients
received second-line treatment (Ciuleanu et al, 2009; Reck et al,
2010). In routine clinical practice, however, the rate can be as low
as 25% (Ramsey et al, 2008). Thus our second-line chemotherapy
rate is closer to what is administered in the general clinical routine,
presumably a consequence of the representative patient inclusion.
The response rates and survival results of oral vinorelbine are
similar to intravenous vinorelbine in advanced NSCLC and breast
cancer (Gralla et al, 2007; Aapro and Finek, 2011). The advantage
of oral vinorelbine is home administration, so that patients,
relatives and health care providers can save valuable time. Besides,
oral vinorelbine induces no phlebitis, in contrast to the
intravenous administration. The disadvantage is more frequent
nausea and vomiting, which can be adequately controlled by
prophylactic antiemetics. It has been shown that patients prefer
taking oral vinorelbine at home instead of intravenous adminis-
tration at the clinic (Jensen et al, 2008). Oral vinorelbine costs
more than intravenous vinorelbine, but this is probably out-
weighed by fewer outpatient visits, quicker and less resource-
demanding administration of the drug, and lower transportation
expenses (Le et al, 2007). Overall, oral vinorelbine can be a useful
alternative to the intravenous formulation in advanced NSCLC,
especially where the distance to the hospital is substantial.
Both CTCAE reporting and HRQoL measurements indicated
slightly more nausea and vomiting in VC patients. The antiemetic
regimen differed a little between the treatment groups (VG patients
received an i.v. glucocorticoid and 5-HT3-antagonist on day 8, VC
patients an oral 5-HT3-antagonist only), but we find it unlikely that
this minor difference should explain more nausea and vomiting in
VC patients. However, the differences between the treatment arms in
HRQoL analyses were below what are considered as clinically
relevant, and the difference in grade III/IV adverse events of nausea
and vomiting was relatively small. A previous meta-analysis failed to
detect any significant difference in nausea and vomiting between
non-platinum and carboplatin-based doublets (Rajeswaran et al,
2008).
In summary, the current study did not confirm prolonged
survival of VG over VC, as first-line treatment in advanced NSCLC.
The minor toxicity differences in favour of VG do not justify a
change in the treatment practice. Thus, platinum-based doublet
chemotherapy remains as the standard first-line treatment.
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CTCAE grade No. of patients % No. of patients % P
Anaemia 0.43
Grade 3 2 1 6 3
Grade 4 1 0 0 0
Neutropenia o0.001
Grade 3 34 16 36 16
Grade 4 14 7 42 19
Thrombocytopenia 0.23
Grade 3 6 3 6 2.7
Grade 4 1 0 3 1
Transfusions
Blood 21 10 36 16 0.09
Platelets 1 0 1 0 0.37
Infection 0.52
Grade 3 33 15 31 14
Grade 4 10 5 8 4
Febrile neutropenia 0.13
Grade 3 5 2 14 6
Grade 4 4 2 4 2
Nausea/vomiting 0.008
Grade 3 8 4 22 10
Grade 4 0 0 4 2
Fatigue 0.89
Grade 3 28 13 25 11
Grade 4 4 2 4 2
Constipation 0.38
Grade 3 12 6 7 3
Grade 4 1 0 2 1
Hospital admissions
Total 100 48 92 44 0.67
Due to side effects 43 20 52 24 0.87
Abbreviations: CTCAE¼Common Terminology Criteria for Adverse Events;
VC¼ vinorelbine plus carboplatin; VG¼ vinorelbine and gemcitabine.
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a b s t r a c t
Objective: Vinorelbine combined with carboplatin is one of the recommended first-line chemotherapy
regimens in advanced non-small cell lung cancer (NSCLC). Vinorelbine, traditionally administered in-
travenously, is also available for oral administration. However, more information regarding the efficacy of
oral versus intravenous therapy is desirable. The Norwegian Lung Cancer Study Group (NLCG) conducted
three first-line NSCLC trials between 2000 and 2009, which included 590 patients who received three
cycles of carboplatin and vinorelbine. Two trials administered intravenous vinorelbine, and one trial
administered oral vinorelbine. The aim of the current study was to compare outcomes between oral and
intravenous vinorelbine in combination with carboplatin as the first-line treatment in advanced NSCLC.
Materials and methods: We retrospectively compared the survival, HRQoL and haematological toxicity
between oral and intravenous vinorelbine using individual data from three trials. Eligible patients re-
ceived a maximum of three 21-day cycles with intravenous carboplatin on day 1 and vinorelbine on day
1 and day 8, at doses of either 60 mg/m2 orally or 25 mg/m2 intravenously.
Results and conclusion: In total, 222 and 368 patients received oral or intravenous vinorelbine, respec-
tively. The overall survival (7.0 vs. 6.9 months), chemotherapy compliance, HRQoL outcomes and toxicity
were similar, although oral patients reported less worsening of constipation and had fewer adverse
events of grade III–IV leukopenia and anaemia.
Oral 60 mg/m² vinorelbine and intravenous 25 mg/m² provided similar survival outcomes. HRQoL
outcomes were similar or in favour of oral vinorelbine. Oral vinorelbine caused less haematological
toxicity.
Microabstract: The study compares the effects of oral to intravenous vinorelbine both combined with
carboplatin in advanced NSCLC. We used data from 590 patients in three previous randomized controlled
trials. Survival and overall HRQoL were similar. Use of oral vinorelbine was associated with less hae-
matological toxicity and patient reported constipation.
& 2016 Elsevier Ltd. All rights reserved.
1. Introduction
The vinorelbine-carboplatin combination is one of the re-
commended first-line treatments in advanced NSCLC. Vinorelbine
is available as an intravenous or oral formulation. The oral for-
mulation allows partial home administration, thus reducing the
use of hospital resources and the number of hospital visits for
patients. The oral formulation also avoids the common problem of
thrombophlebitis associated with intravenous vinorelbine. The
advantages of oral vinorelbine in combination with carboplatin
has been outlined in a recent review [1].
To date, no randomised phase III trial has directly compared
oral with intravenous vinorelbine in advanced NSCLC. Moreover,
the two largest randomised phase II trials administered vinor-
elbine as a single agent. One of these trials (189 patients) found a
lower response rate with oral vinorelbine [2], while the other trial
(114 patients) indicated similar response rates [3]. Only one small,
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randomised trial (61 patients) has addressed the specific issue of
oral versus intravenous vinorelbine in the commonly used com-
bination with carboplatin [4]. That trial demonstrated patients’
preference for oral vinorelbine, if equivalent efficacy could be
presumed.
Two relatively large trials have compared oral vinorelbine with
other regimens. A phase III trial (381 patients) compared an al-
ternating intravenous day 1/oral vinorelbine day 8 regimen with
docetaxel, both in combination with cisplatin, and found similar
response rates and survival outcomes [5]. A phase II trial (153
patients) compared oral vinorelbine with pemetrexed, both com-
bined with cisplatin and then continued as a single agent in
maintenance therapy, and found no significant differences in re-
sponse rates or survival [6].
Until now, no phase III trial has directly compared oral versus
intravenous vinorelbine, and no large randomised trial has ad-
dressed the combination with carboplatin. Such a study would
have to be very large; thus, alternative study designs are needed.
Therefore, we assembled data from three Norwegian advanced
NSCLC trials, aiming to perform a retrospective comparison of oral
versus intravenous vinorelbine, both in combination with carbo-
platin. The current paper reports the results from this comparison.
2. Material and methods
2.1. Aim, design and approval of the study
The aim of the current study was to compare oral versus in-
travenous vinorelbine, both in combination with carboplatin, as
first-line treatment in advanced NSCLC. The design is a retro-
spective comparison of individual data from three randomised
chemotherapy trials [7–9]. The end points were overall survival,
HRQoL, and haematological toxicity. The Regional Committee for
Medical Research Ethics, Northern Norway, approved the study.
2.2. Patients and treatment
Eligible patients were those who were planned for three cycles
of vinorelbine and carboplatin in the three above-mentioned trials.
All patients had NSCLC stage IV or stage IIIB not eligible for cura-
tive treatment, WHO performance status (PS) 0–2, and no other
clinically active malignancy. All trials allowed brain metastases
and defined no upper age limit, but they required adequate bone
marrow, renal, and hepatic function. All patients had undergone a
baseline CT scan of the chest and upper abdomen for disease
staging [10].
The first two trials [7,8] administered intravenous vinorelbine
at a dose of 25 mg/m2 at day 1 and day 8 and carboplatin ac-
cording to Chatelut's formula [11] with an AUC of 4 at day 1. An-
tiemetic prophylaxis with intravenous dexamethasone and on-
dansetron on day 1 was mandatory, while it was optional at day 8.
The patients in the last trial [9] took capsules with vinorelbine
at a dose of 60 mg/m² at days 1 and 8 along with a light meal and
received carboplatin according to Calvert's formula [12] with an
AUC of 5, using the Cockroft Gault formula to estimate creatinine
clearance at day 1. Antiemetic prophylaxis on day 1 was the same
as that in the two first trials, but the protocol recommended oral
ondansetron twice on day 8.
Body surface area was calculated using the same formula in all
three trials (Dubois D and Dubois EF, 1916). Patients Z75 years of
age received 75% of the calculated drug doses from the first cycle
in the last two trials.
Before randomisation, all patients reported HRQoL on the
EORTC QLQ-C30 questionnaires and the lung cancer specific QLQ-
LC 13 module [13]. A central study office mailed additional
questionnaires directly to the patients at 3, 6, 9 and 17 weeks (18
weeks in the first study).
Leucocyte and thrombocyte counts and haemoglobin con-
centration were recorded until three weeks after the last cycle. The
three trials had similar rules for dose reduction or postponement
of chemotherapy in cases of severe toxicity.
2.3. Analysis
We defined survival as the time from randomisation (in the
patients’ respective trial) until death and compared the oral and
intravenous treatment groups with the Kaplan-Meier method,the
log-rank test and Cox regression. CTCAE version 3.0 was used for
categorising haematological toxicity, and groups were compared
using a chi-squared test. HRQoL data were scored according to the
EORTC scoring manual, and the group mean scores and changes in
scores from baseline to each time point (score change) in each
treatment group were compared using a t-test. No imputation was
performed for missing values. Differences 410 points between
treatment groups were considered as clinically relevant. We also
performed subgroup analyses according to age (o75 vs. Z75
years), gender, PS (0–1 vs. 2), and disease stage (IIIB vs. IV). Che-
motherapy compliance was also compared in the patient sub-
groups defined by the baseline scores on the QLQ nausea vomiting
items (absence of such symptoms vs. at least one positive score on
one of the questions).
3. Results
We included 222 patients on oral vinorelbine and 368 patients
on intravenous vinorelbine. The groups were demographically si-
milar, with the exception of fewer stage IIIB patients in the oral
vinorelbine group (Table 1).
The mean number of chemotherapy cycles was 2.7 in both
groups. Compliance in the subgroups as defined by baseline re-
porting of nausea and vomiting was similar (absence of such
symptoms; 2.8 cycles in both the oral and intravenous vinorelbine
groups, at least one positive score; 2.6. cycles in both groups).
Three patients received no study treatment (oral: one patient;
intravenous: two patients) and were not included in the toxicity
analysis.
The median survival was 7.0 months in the oral group and
6.9 months in the intravenous group (log rank p¼0.717) (Fig. 1). A
multivariate Cox regression analysis of 440 patients in the two last
trials (the data from the 150 patients in the first trial lacked date
for second-line treatment) detected no difference between oral vs.
intravenous vinorelbine [95% CI], HR 0.97 [0.79–1.18], when ad-
justing for receiving vs. not receiving second-line therapy (time-
dependent co-variate), HR 1.05 [0.83–1.33]; adenocarcinoma vs.
other histology, HR 0.87 [0.72–1.07]; stage IIIB vs. IV, HR 0.89
[0.70–1.14]; men vs. women, HR 1.01 [0.83–1.23]; PS 0–1 vs. 2, HR
0.52 [0.41–0.64]; age Z75 vs o75, HR 0.85 [0.66–1.09].
Patients on oral vinorelbine had significantly less CTCAE grade
III–IV anaemia (oral: 2.7%; IV: 5.0%; p¼0.010) and leukopenia
(oral: 22%; IV: 41%; po0.001), while the occurrence of thrombo-
cytopenia did not differ between the treatment groups (oral: 4%;
IV: 2%; p¼0.264). Patients on oral vinorelbine had less leukopenia
in both the gender and age subgroups, while the difference in
anaemia was statistically significant only for males (Table 2).
The completion rates of the HRQoL questionnaires by week 17
were 88% and 85% in the oral and intravenous groups, respectively.
No differences in the mean scores between the treatment groups
exceeded 10 points (Table 3). An analysis of the change in scores
showed that the patients on oral vinorelbine, compared with those
on intravenous vinorelbine, reported (only statistically significant
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differences 4 10 points are mentioned) less worsening of per-
ipheral neuropathy at 6 and 9 weeks, constipation at 3 weeks,
alopecia at 9 and 17 weeks and social functioning at 17 weeks.
Additionally, patients on intravenous vinorelbine reported a
greater improvement in coughing at 6 weeks. Fig. 2 shows the
score changes that differed by at least 10 points on at least one
time point (Fig. 2). All of the other group differences were below
10 points. Subgroup analyses according to age (o75 vs. Z75
years), gender, PS (0–1 vs. 2), and disease stage (IIIB vs. IV) were
consistent with the primary findings (data not shown).
The percentage of patients receiving at least one regimen of
systemic second-line therapy (chemotherapy or TKIs) was 44% in
the oral and 28% in the intravenous group.
4. Discussion
In this largest comparison of oral versus intravenous vinor-
elbine in combination with carboplatin as first-line treatment for
advanced NSCLC, we found no significant difference in survival
between the two groups. The HRQoL outcomes of the groups were
similar, except for some minor differences mostly in favour of the
oral administration form of vinorelbine. Furthermore, fewer oral
vinorelbine patients had grade III-IV leukopenia and anaemia.
Our findings are generally in accordance with those of the
published literature [1]. An exception is that two previous studies
[2,3] reported that compared with intravenous vinorelbine, oral
vinorelbine was associated with more nausea and vomiting, which
we did not observe in our study. The explanation of this difference
is probably that we advised the patients on oral vinorelbine to use
antiemetic prophylaxis. Furthermore, we recommended that pa-
tients combine oral vinorelbine with a light meal, as previously
recommended [14]. The current study supports both
recommendations.
A limitation of the current study is its retrospective design,
introducing possible biases due to the inclusion of different patient
populations, varying second-line therapies, and different formulas
for carboplatin dosage. Furthermore, the trials did not assess re-
sponse rates or progression free survival. The baseline demo-
graphic data were similar in the two populations, except for more
stage IIIB patients in the intravenous group. The use of Calvert's
formula with AUC 5 vs. Chatelut's formula with AUC 4 tends to
result in a higher dose for women, while the effect is opposite in
men (our calculations). However, the consistent findings of greater
leukopenia with intravenous vinorelbine across gender and age
subgroups rules out different carboplatin dosing as an explanation
for greater leukopenia from intravenous vinorelbine. Because the
subgroup analyses were consistent with the main findings, we
consider that the methodological challenges in this study do not
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Fig. 1. Median OS: Oral 7.0 months IV: 6,9 months log-rank p¼0.717.
Table 2
Grade III–IV haematological toxicity.
Oral n¼221 Intravenous n¼366
n % n % p
Anaemia 6 3 18 6 0.010
Female 1 1 2 2 0.533
Male 5 4 16 7 0.013
Z75 year 1 3 4 6 0.031
o75 year 5 3 14 5 0.060
Stage IIIB 0 0 3 3 0.114
Stage IV 6 3 15 6 0.034
PS 0-1 2 1 12 5 0.036
PS 2 4 7 6 6 0.032
Leukopenia 49 22 150 42 o0.001
Female 21 22 45 34 0.026
Male 28 22 105 46 o0.001
Z75 year 5 14 35 49 o0.001
o75 year 44 24 115 39 0.001
Stage IIIB 8 24 36 36 0.332
Stage IV 41 22 114 43 o0.001
PS 0-1 41 25 107 41 o0.001
PS 2 8 15 43 41 o0.001
Thrombocytopenia 9 4 6 2 0.264
Female 3 3 2 2 0.081
Male 6 5 4 2 0.167
Z75 year 0 0 1 1 0.157
o75 year 9 5 5 2 0.243
Stage IIIB 0 0 3 3 0.509
Stage IV 9 5 3 1 0.086
PS 0-1 5 3 5 2 0.572
PS 2 4 7 1 1 0.115
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Table 3
Completion rates of the HRQoL-questionnaires and mean scores for reported values.
Baseline 3 weeks 6 weeks 9 weeks 17 weeks Total
oral iv oral iv oral iv oral iv oral iv oral iv
Alive 222 368 219 360 211 345 201 333 164 274 1017 1681
No. of delivered forms 222 358 203 315 184 303 168 269 130 204 907 1449
Completion rate (%) 100 97 93 88 87 88 84 81 79 74 88 85
Global QoL 55 51 54 55 55 52 55 53 54 51
Physical functioning 65 62 59 58 59 57 60 58 59 57
Role functioning 53 50 49 45 48 45 49 45 48 45
Emotional functioning 74 70n 74 75 74 75 76 76 77 73
Cognitive functioning 81 81 79 82 82 80 80 80 81 78
Social functioning 61 64 58 58 62 58 62 60 62 58
Fatigue 48 49 50 51 48 52 48 51 47 48
Nausea and vomiting 12 12 16 13 17 14n 15 13 12 10
Pain (C30-module) 35 34 33 28 31 29 31 29 32 31
Dyspnoea 47 50 43 46 44 44 45 47 49 50
Insomnia 34 34 30 31 27 29 27 29 28 27
Apetite loss 33 35 36 32 33 34 30 31 32 31
Constipation 27 23 31 37 30 34 31 36 30 27
Diarrhoea 14 14 17 12n 16 11n 13 10 14 13
Financial difficulties 10 9 9 10 10 10 8 9 9 12
Dyspnoea (LC13-module) 40 41 40 39 36 40 33 41nn 37 43n
Coughing 38 45nn 34 35 36 29n 31 31 32 35
Heamoptysis 4 6 6 4 4 4 3 3 3 4
Sore mouth 8 6 9 11 11 11 8 9 10 9
Dysphagia 12 10 9 9 10 9 10 11 11 14
Peripheral neuropathy 16 11nn 13 15 13 17 13 20nn 18 19
Alopecia 16 5nn 15 7nn 15 12 15 14 12 16
Pain in chest 19 22 19 21 18 22 16 22n 18 25n
Pain in arm or shoulder 19 23 22 22 20 25 17 19 19 20
Pain in other parts of body 30 28 28 27 29 27 27 29 28 28
t-test, HRQoL ¼ Health related Quality of life, as reported on the EORTC QLQ-C30 and LC13 modules displayed as mean scores of all reported values.




Fig. 2. Mean score changes in HRQoL dimensions with at least one group difference 410 points, as reported on the EORTC QLQ-C30 form. A higher symptom score indicates
more symptoms, while a a higher functioning score indicates better functioning. The error bars display 95% confidence intervals.
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The high completion rate of HRQoL questionnaires throughout
the treatment period in all three included trials is an important
strength of this study. Moreover, to the best of our knowledge, the
current study is the largest HRQoL comparison to date between
oral and intravenous vinorelbine. It should be noted that patients
returned the EORTC QLQ-C30 and QLQ-LC13 forms with intervals
of 3 weeks, principally reporting symptoms from only the pre-
ceding week. Therefore, it is possible that the symptom burden
from constipation among intravenous vinorelbine patients could
have been worse shortly after the last vinorelbine administration
at day 8 in every cycle. However, the available HRQoL results in our
study support the conclusion that oral vinorelbine 60 mg/m²,
compared with intravenous 25 mg/m2, is equally well tolerated.
We observed that more patients on oral than intravenous vi-
norelbine received second-line treatment. One main reason for
this is probably that both erlotinib and pemetrexed were in-
troduced as second-line treatments for advanced NSCLC during
the interval between the two intravenous vinorelbine studies and
oral vinorelbine study. One may presume that this procedure can
confound survival analysis. However, the difference in the use of
second-line therapy between the treatment groups was modest
(44% vs. 28%), and we assume that this difference is too small to
substantially influence the survival outcomes in the total study
population.
Compared with recent publications on systemic treatment of
NSCLC, the overall survival was poor in our study cohort. Reasons
may be differences in treatment and eligibility criteria. In contrast
to updated guidelines [15], maintenance treatment with peme-
trexed to patients with non-squamous histology was not im-
plemented, and the patients received only three instead of four
courses of chemotherapy. We included also a large proportion of
PS 2 patients, and allowed brain metastases. The impact of each of
these differences is difficult to assess accurately, but they may
together explain the relatively short overall survival.
Studies on the bioavailability of oral vinorelbine have shown
variable results. One trial showed that the oral vinorelbine dosage
of 60 mg/m² is equal to an intravenous dosage of 25 mg/m², cor-
responding to the reported bioavailability of 43% with the oral
formulation [16]. Meanwhile, other studies have reported lower
bioavailability of the oral formulation, e.g., 36–38% (Puozzo and
Gridelli, 2004), 38–40% (Gebbia and Puozzo, 2005), and 27% [17].
Thus, we cannot rule out that the observation of less constipation
and less leukopenia in the oral treatment group in the present
study simply reflects a lower than assumed bioavailability of oral
vinorelbine and that the administration form itself is not the cause
for the observed differences.
A trial with cisplatin and vinorelbine in advanced NSCLC
showed that the day 8 haemogram could be safely omitted in
patients with PSo2 [18]. One should, however, consider that
carboplatin is more toxic than cisplatin on the bone marrow.
Hence, whether a day 8 haemogram is necessary is, so far, unclear
for patients receiving vinorelbine in combination with carboplatin
[19]. If the day 8 haemogram can be safely omitted, it will imply
that the day 8 treatment can be administered as an entirely at
home treatment. Such an approach can save valuable time for both
the patients and their relatives, and save hospital resources.
In summary, our retrospective comparison of oral and in-
travenous vinorelbine, in combination with carboplatin, showed
no difference in overall survival. HRQoL outcomes were similar or
in favour of oral vinorelbine. We conclude that oral 60 mg/m² vi-
norelbine treatment, compared with intravenous 25 mg/m², is well
tolerated. Moreover, it causes fewer grades III–IV leukopenia and
anaemia, and fewer patients reported worsening of constipation.
Whether these differences are related to different routes of ad-
ministration or differences regarding vinorelbine bioavailability is
not clear.
Clinical practice points
This study is the first larger comparison of oral to intravenous
vinorelbine in advanced NSCLC.
Survival and overall HRQoL in patients receiving oral was not
inferior to intravenous vinorelbine.
Use of oral vinorelbine was associated with less haematological
toxicity.
Clinicians can consider treating patients with advanced NSCLC
with oral vinorelbine for its ease of use.
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